MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy
MRTX-500 II期试验:Sitravatinib联合Nivolumab治疗接受或正在接受免疫检查点抑制剂治疗或化疗后进展的非鳞状非小细胞肺癌患者
期刊:Journal of Thoracic Oncology
影响因子:20.8
doi:10.1016/j.jtho.2023.02.016
He, Kai; Berz, David; Gadgeel, Shirish M; Iams, Wade T; Bruno, Debora S; Blakely, Collin M; Spira, Alexander I; Patel, Manish R; Waterhouse, David M; Richards, Donald A; Pham, Anthony; Jotte, Robert; Hong, David S; Garon, Edward B; Traynor, Anne; Olson, Peter; Latven, Lisa; Yan, Xiaohong; Shazer, Ronald; Leal, Ticiana A
Checkpoint
肺癌
肿瘤
肿瘤免疫
细胞生物学
免疫/内分泌